Trial · NCT07880418
Ai-Chi in Individuals With Multiple Sclerosis
NCT07880418, Not applicable, Completed, Kirsehir Ahi Evran Universitesi
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Ai-Chi in Individuals With Multiple Sclerosis. Trials, record NCT07880418. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07880418
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ai-Chi in Individuals With Multiple Sclerosis
- NCT number
- NCT07880418
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 20 participants, actual
- Lead sponsor
- Kirsehir Ahi Evran Universitesi
- Conditions
- Multiple Sclerosis
- Interventions
- Ai-Chi exercise, Land-Based Exercise
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Lower Extremity Strength Assessment | Baseline and immediately after the 5-week intervention | A handheld dynamometer will be used to assess lower extremity muscle strength. Participants will be informed about the test procedure before testing. Each test will be performed three times with maximal effort, and the mean value will be recorded in Newtons. The quadriceps femoris, hamstrings, hip flexors, hip extensors, hip adductors, and hip abductors will be evaluated. Each test will be repeated three times, with a 30-second rest period between measurements. When necessary, the therapist will stabilize the relevant extremity during testing. For the assessment of the quadriceps femoris, the participant will sit at the edge of a treatment table with the hip and knee flexed at 90°. The dynamometer will be placed approximately 1-2 cm proximal to the malleoli on the distal tibia. The participant will then be instructed to perform knee extension with maximal force, and the results of the three maximal trials will be recorded. |
| Primary | Upper Extremity Strength Assessment | Baseline and immediately after the 5-week intervention | The Jamar hand dynamometer will be used to assess upper extremity muscle strength. Participants will be seated in a chair with their back supported. The tested shoulder will be positioned in adduction, with the elbow flexed at 90°, while the forearm and wrist will be maintained in a neutral position. Prior to testing, participants will be informed about the procedure. The test will be performed three times with maximal effort, and the mean value will be recorded in kilograms. |
| Primary | Balance Assessment | Baseline and immediately after the 5-week intervention | The Berg Balance Scale (BBS) will be used to assess balance. The scale consists of 14 items, each scored from 0 (unable to perform) to 4 (normal performance). The test includes tasks such as forward reaching, standing with the eyes open and closed, and standing on one leg. A total score of 0-20 indicates a high level of balance impairment, 21-40 indicates a moderate level of balance impairment, and 41-56 indicates a low level of balance impairment. |
| Primary | Fatigue Assessment | Baseline and immediately after the 5-week intervention | The Fatigue Impact Scale (FIS) will be used to assess fatigue severity. The FIS is a self-report scale consisting of 40 items covering physical, psychosocial, and cognitive domains. Each item is scored from 0 (never) to 4 (almost always). The total score ranges from 0 to 160, with higher scores indicating a greater impact of fatigue on the individual. |
| Secondary | Quality of Life Assessment | Baseline and immediately after the 5-week intervention | The Multiple Sclerosis Quality of Life-54 (MSQOL-54) questionnaire, which is specifically designed for individuals with MS, will be used to assess quality of life. The questionnaire was developed based on the SF-36 Health Survey. In addition to the SF-36 items, 18 additional items assessing domains such as pain, cognitive function, and physical function were incorporated. The questionnaire consists of 54 items, and each domain is scored separately according to its specific scoring system. Scores range from 0 to 100, with higher scores indicating better quality of life. |
| Secondary | Mobility Assessment | Baseline and immediately after the 5-week intervention | The Multiple Sclerosis Walking Scale-12 (MSWS-12), specifically developed for individuals with multiple sclerosis (MS), will be used to assess walking ability and its limitations. The scale consists of 12 items rated on a 5-point Likert scale, ranging from 1 (not at all) to 5 (extremely). The items assess the impact of MS on walking ability, including walking distance, speed, balance, and the need for support. The raw total score ranges from 12 to 60, with higher scores indicating greater walking limitations. The raw score can be transformed to a 0-100 scale according to the instrument's scoring guidelines, with higher transformed scores also indicating greater walking impairment. |
| Secondary | Mobility Assessment | Baseline and immediately after the 5-week intervention | Another method that will be used to assess mobility is the Timed Up and Go (TUG) Test. Participants will be informed about the test procedure before testing. A distance of 3 meters will be marked between the chair and a designated turning point. The participant will sit in a chair with a backrest and armrests. Following the command "Go," the participant will stand up from the chair, walk 3 meters at their normal walking speed, turn around at the designated point, walk back 3 meters, and sit down in the chair again. The time required to complete the task will be recorded in seconds. A shorter completion time indicates better mobility. |
| Secondary | Cognitive Function Assessment | Baseline and immediately after the 5-week intervention | The Brief International Cognitive Assessment for MS (BICAMS) is a brief assessment battery specifically developed for individuals with MS to evaluate cognitive function. It consists of three subtests: the Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-Second Edition (CVLT-II), and the Brief Visuospatial Memory Test-Revised (BVMT-R). Participants will be informed about the procedures for each subtest before the assessment. |
| Secondary | Cognitive Function Assessment | Baseline and immediately after the 5-week intervention | The Symbol Digit Modalities Test (SDMT) is used to assess information-processing speed and consists of nine digits and nine corresponding symbols. Participants are required to write the digits corresponding to the presented symbols as quickly and accurately as possible within 90 seconds. Following one practice trial, the test will be administered. The numbers of correct and incorrect responses will be recorded. |
| Secondary | Cognitive Function Assessment | Baseline and immediately after the 5-week intervention | The California Verbal Learning Test-Second Edition (CVLT-II) is used to assess verbal-auditory learning and memory. The test consists of 16 words representing categories such as vegetables, household items, animals, and vehicles. The examiner will read the 16 words aloud in a clear and audible voice five consecutive times. After each presentation, participants will be asked to recall as many words as possible, and the recalled words will be recorded. A maximum of 80 words can be recalled across the five trials. The test will be administered without a time limit, and the numbers of correct and incorrect responses will be recorded. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Symbol Coding | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07880418
GET https://conductscience.org/api/trials/v1/NCT07880418/registered